Table 2.
Association between clinicopathological characteristics and HALP.
| Cohort characteristics | HALP value | ||
|---|---|---|---|
| Low | High | P value | |
| Age | 0.019 | ||
| <65 | 24(32.9) | 196(47.7) | |
| ≥65 | 49(67.1) | 215(52.3) | |
| Gender | 0.013 | ||
| female | 18(24.7) | 55(13.4) | |
| male | 55(75.3) | 356(86.6) | |
| Smoking history | 0.204 | ||
| no | 55(75.3) | 279(67.9) | |
| yes | 18(24.7) | 132(32.1) | |
| Alcohol-drinking history | 0.646 | ||
| no | 65(89.0) | 358(87.1) | |
| yes | 8(11.0) | 53(12.9) | |
| Hypertension | 0.890 | ||
| no | 52(71.2) | 296(72.0) | |
| yes | 21(28.8) | 115(28.0) | |
| Histology type | 0.553 | ||
| transitional cell carcinoma | 70(95.9) | 387(94.2) | |
| non-transitional cell carcinoma | 3(4.1) | 24(5.8) | |
| Grade | 0.178 | ||
| 2 | 13(17.8) | 102(24.8) | |
| 3 | 60(82.2) | 304(74.0) | |
| T-stage | <0.001 | ||
| NMIBC | 7(9.6) | 146(35.5) | |
| MIBC | 66(90.4) | 265(64.5) | |
| N-stage | 0.725 | ||
| negative | 61(83.6) | 350(85.2) | |
| positive | 12(16.4) | 61(14.8) | |
| M-stage | 0.026 | ||
| negative | 70(95.9) | 409(99.5) | |
| positive | 3(4.1) | 2(0.5) | |
| Adjunctive chemotherapy | 0.170 | ||
| yes | 16(21.9) | 68(16.5) | |
| no | 57(78.1) | 343(83.5) | |
| ASA grade | 0.010 | ||
| 1&2 | 54(74.0) | 353(85.9) | |
| 3&4 | 19(26.0) | 58(14.1) | |
| Anemia | <0.001 | ||
| absent | 13(17.8) | 327(79.6) | |
| present | 60(82.2) | 84(20.4) | |
| Hypoalbuminemia | <0.001 | ||
| absent | 47(64.4) | 394(95.9) | |
| present | 26(35.6) | 17(4.1) | |
| PLR | <0.001 | ||
| low | 23(31.5) | 397(96.6) | |
| high | 50(68.5) | 14(3.4) | |
Data are shown as n (%).
MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer; ASA, American Society of Anesthesiologists; PLR: platelet to lymphocyte ratio.